Taysha Gene Therapies’ (TSHA) “Buy” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a $8.00 target price on the stock.

A number of other equities analysts have also commented on TSHA. JMP Securities raised their price objective on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the company a “market outperform” rating in a research report on Thursday, May 29th. Chardan Capital raised their price objective on shares of Taysha Gene Therapies from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, May 29th. Canaccord Genuity Group raised their price objective on shares of Taysha Gene Therapies from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, June 3rd. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Finally, Citigroup restated an “outperform” rating on shares of Taysha Gene Therapies in a research report on Thursday, May 29th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $7.57.

Taysha Gene Therapies Trading Down 6.8%

NASDAQ:TSHA opened at $2.61 on Tuesday. The company has a market cap of $560.27 million, a P/E ratio of 4.14 and a beta of 1.04. The stock’s fifty day moving average price is $2.10 and its two-hundred day moving average price is $1.93. Taysha Gene Therapies has a 1 year low of $1.05 and a 1 year high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The firm had revenue of $2.30 million for the quarter, compared to the consensus estimate of $1.48 million. During the same quarter in the prior year, the business posted ($0.10) earnings per share. As a group, analysts expect that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Activity at Taysha Gene Therapies

In other news, major shareholder Paul B. Manning bought 750,000 shares of Taysha Gene Therapies stock in a transaction that occurred on Friday, May 30th. The shares were acquired at an average price of $2.75 per share, with a total value of $2,062,500.00. Following the completion of the purchase, the insider now directly owns 2,841,704 shares in the company, valued at $7,814,686. The trade was a 35.86% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 2.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in TSHA. Ground Swell Capital LLC purchased a new position in shares of Taysha Gene Therapies during the fourth quarter worth approximately $25,000. Cibc World Markets Corp purchased a new position in shares of Taysha Gene Therapies during the fourth quarter worth approximately $28,000. E Fund Management Co. Ltd. purchased a new position in shares of Taysha Gene Therapies during the fourth quarter worth approximately $31,000. Hsbc Holdings PLC raised its stake in shares of Taysha Gene Therapies by 65.6% during the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock worth $36,000 after acquiring an additional 8,076 shares in the last quarter. Finally, AXQ Capital LP purchased a new position in shares of Taysha Gene Therapies during the fourth quarter worth approximately $39,000. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.